Evaluating the Risk of Venous Thromboembolism in Transfeminine and Gender Diverse People: A Retrospective Analysis
Authors' conclusion
The prevalence of VTE in our cohort was lower than previously observed. VTE was not associated with any one risk factor, including estrogen use, when controlling for age, race, and the number of comorbidities. Those of advanced age and those with multiple cardiometabolic comorbidities may benefit from increased surveillance and mitigation of modifiable risk factors.
Study context
- Population
- Transfeminine and gender diverse adults receiving care within a large urban health system
- Participants
- 2,126 participants
- Exposure
- Patients with vs without a history of venous thromboembolism (VTE); association of VTE with insurer, estrogen use and comorbidities
- Outcome
- Prevalence of VTE and ORs for association of VTE with insurer, estrogen use and select comorbidities
Methodological detailschart review, single health system
- Chart review
- Single health system
Main finding
As reported in the abstract
Prevalence of VTE history
- History of VTE documented in cohort
- 0.8%
- Univariate analyses: hyperlipidemia associated with increased odds of VTE
- P < .001
- Univariate analyses: DM associated with increased odds of VTE
- P < .05
- Univariate analyses: insurer associated with increased odds of VTE
- P < .05
Observational data: associations, not effects.
Further findings
Characteristics of VTE vs no VTE
- VTE: older
- P < 0.001
- VTE: more often Hispanic or Black vs White or Asian
- P < 0.05
- VTE: more likely Medicaid or Medicare
- P < 0.01
- VTE: greater prevalence of hyperlipidemia
- P < 0.001
- VTE: greater prevalence of DM
- P < 0.05
- VTE: greater prevalence of hypercoagulable conditions
- P < 0.001
Original publication
Evaluating the Risk of Venous Thromboembolism in Transfeminine and Gender Diverse People: A Retrospective Analysis. Endocr Pract. Published 2 September 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →